AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.39B
1-Year Est. Return
230.19%
This Fund
S&P 500
1 Year Est. Return
+230.19%
AUM
$1.39B
AUM Growth
+$317M
(+29%)
Holding
118
Top Buys
| 1 | +$34.5M | |
| 2 | +$28M | |
| 3 | +$19.1M | |
| 4 |
Roivant Sciences
ROIV
|
+$17.8M |
| 5 |
Forte Biosciences
FBRX
|
+$17.3M |
Top Sells
| 1 | +$66.7M | |
| 2 | +$56.3M | |
| 3 | +$42.8M | |
| 4 |
MRUS
Merus
MRUS
|
+$26.9M |
| 5 |
Soleno Therapeutics
SLNO
|
+$13.5M |
Sector Composition
| 1 | Healthcare | 96.69% |
| 2 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$4.85B
| $93.2M | 6.7% |
1,234,926
+61,500
|
|
||
2
Insmed
INSM
$31.2B
| $78.3M | 5.63% |
450,000
|
|
||
|
ABVX
3
Abivax
ABVX
$8.94B
| $68.1M | 4.89% |
505,000
+145,000
|
|
||
4
Ventyx Biosciences
VTYX
$1B
| $58.6M | 4.21% |
6,484,558
+2,560,143
|
|
||
5
Xenon Pharmaceuticals
XENE
$3.29B
| $56M | 4.03% |
1,250,000
-150,000
|
|
||
6
Praxis Precision Medicines
PRAX
$9.17B
| $54.5M | 3.92% |
+185,000
|
|
||
7
Cytokinetics
CYTK
$7.51B
| $50.8M | 3.65% |
800,000
+450,000
|
|
||
8
Spyre Therapeutics
SYRE
$3.34B
| $46.9M | 3.37% |
1,432,591
+13,292
|
|
||
9
Wave Life Sciences
WVE
$2.57B
| $45.9M | 3.3% |
2,700,000
+600,000
|
|
||
10
Teva Pharmaceuticals
TEVA
$39.3B
| $43.7M | 3.14% |
1,400,000
|
|
||
|
11
Roivant Sciences
ROIV
$20.1B
| $36.9M | 2.65% |
1,700,000
+900,000
|
|
||
12
Arcellx
ACLX
$6.59B
| $34.1M | 2.45% |
523,725
+23,725
|
|
||
13
Nuvalent
NUVL
$7.87B
| $32.5M | 2.33% |
322,633
-61,784
|
|
||
14
Lexeo Therapeutics
LXEO
$520M
| $31.8M | 2.28% |
3,200,000
-670,527
|
|
||
15
Alkermes
ALKS
$4.99B
| $28M | 2.01% |
1,000,000
-250,000
|
|
||
|
16
Forte Biosciences
FBRX
$384M
| $27M | 1.94% |
+989,490
|
|
||
17
Trevi Therapeutics
TRVI
$1.61B
| $26.9M | 1.93% |
2,150,172
-649,828
|
|
||
18
Mineralys Therapeutics
MLYS
$2.32B
| $26.5M | 1.9% |
730,000
-20,000
|
|
||
19
BridgeBio Pharma
BBIO
$12.7B
| $24.5M | 1.76% |
320,000
+255,000
|
|
||
|
ORKA
20
Oruka Therapeutics
ORKA
$1.63B
| $24.3M | 1.75% |
802,342
-156,838
|
|
||
21
Terns Pharmaceuticals
TERN
$4.57B
| $22.2M | 1.6% |
+550,000
|
|
||
22
AnaptysBio
ANAB
$1.52B
| $21.6M | 1.55% |
+444,692
|
|
||
23
Cullinan Oncology
CGEM
$945M
| $20M | 1.44% |
1,932,106
+1,668,289
|
|
||
24
Avalo Therapeutics
AVTX
$333M
| $19.1M | 1.37% |
1,051,054
+44,837
|
|
||
25
Nurix Therapeutics
NRIX
$1.63B
| $18.4M | 1.32% |
967,620
|
|